WASHINGTON, Aug. 12 -- National Institutes of Health has issued a notice called: NIH Owned Invention Available for License: Drug-Regulatable, Inducible Expression of Membrane-Bound Interleukin 12 (DRIM-IL-12) for Use in Adoptive Cell Therapy.
The notice was published in the Federal Register on Aug. 12 by Richard U. Rodriguez, Associate Director, Technology Transfer Center, National Cancer Institute.
Summary: Scientists at the National Cancer Institute (NCI) have developed a novel tightly regulated drug-responsive, membrane-bound IL-12 cytokine platform, that enhances anti-tumor efficacy in adoptive cell therapy (ACT) with engineered T-cells (CAR, TCR, TILs) while improving safety. The NCI seeks research co-development partners and/or lice...